การทดสอบทั้งสองอย่างตรวจจับการอักเสบของลำไส้ที่เกิดจากนิวโทรฟิล แต่แคลโปรเทคตินมักจะเป็นเครื่องมือติดตามเชิงปริมาณที่มีประโยชน์มากกว่า ผลลัพธ์ที่ถูกต้องคือผลลัพธ์ที่เปลี่ยนแปลงการตัดสินใจทางคลินิกครั้งต่อไป ไม่ใช่ผลลัพธ์ที่ระบุว่าคุณเป็น IBD.
This guide was written under the leadership of ດຣ. ທອມັສ ໄຄລນ໌, MD ໂດຍຮ່ວມມືກັບ ຄະນະທີ່ປຶກສາດ້ານການແພດ Kantesti AI, ລວມທັງການປະກອບສ່ວນຈາກສາດສະດາຈານ ດຣ. ຮານ ເວເບີ ແລະ ການທົບທວນທາງການແພດໂດຍ ດຣ. ຊາຣາ ມິດເຊວ, MD, PhD.
ທອມັສ ໄຄລນ໌, MD
ຫົວໜ້າເຈົ້າໜ້າທີ່ແພດ, Kantesti AI
លោកវេជ្ជបណ្ឌិត Thomas Klein ជាវេជ្ជបណ្ឌិតឯកទេសជំងឺឈាមដែលមានការបញ្ជាក់ពីក្រុមប្រឹក្សា (board-certified) និងជាវេជ្ជបណ្ឌិតផ្នែកជំងឺខាងក្នុង (internist) មានបទពិសោធន៍ជាង 15 ឆ្នាំក្នុងវិស័យវេជ្ជសាស្ត្រមន្ទីរពិសោធន៍ និងការវិភាគផ្នែកព្យាបាលដែលជួយដោយ AI។ ក្នុងតួនាទីជានាយកវេជ្ជសាស្ត្រ (Chief Medical Officer) នៅ Kantesti AI លោកផ្តល់ការត្រួតពិនិត្យផ្នែកវេជ្ជសាស្ត្រលើភាពត្រឹមត្រូវនៃសុខភាពនៃ neural network ដែលជាកម្មសិទ្ធិ (proprietary)។ លោកវេជ្ជបណ្ឌិត Klein បានបោះពុម្ពផ្សាយអំពីការបកស្រាយ biomarker និងការធ្វើរោគវិនិច្ឆ័យក្នុងមន្ទីរពិសោធន៍។.
ຊາຣາ ມິດເຊວ, MD, PhD
ຫົວໜ້າທີ່ປຶກສາດ້ານການແພດ - ພະຍາດວິທະຍາທາງດ້ານຄລີນິກ ແລະ ການແພດພາຍໃນ
Dr. Sarah Mitchell is a board-certified clinical pathologist with over 18 years of experience in laboratory medicine and diagnostic analysis. She holds specialty certifications in clinical chemistry and has published extensively on biomarker panels and laboratory analysis in clinical practice.
ສາດສະດາຈານ ດຣ. ຮານສ໌ ເວເບີ, ປະລິນຍາເອກ
ອາຈານສອນວິຊາການແພດຫ້ອງທົດລອງ ແລະ ຊີວະເຄມີທາງດ້ານຄລີນິກ
Prof. Dr. Hans Weber brings 30+ years of expertise in clinical biochemistry, laboratory medicine, and biomarker research. Former President of the German Society for Clinical Chemistry, he specializes in diagnostic panel analysis, biomarker standardization, and AI-assisted laboratory medicine.
- แคลโปรเทคติน ต่ำกว่า 50 µg/g โดยทั่วไปแล้วจะให้ความสบายใจในผู้ใหญ่ที่สงสัยว่าเป็น IBS เมื่อไม่มีสัญญาณเตือน.
- แลคโตเฟอร์ริน เป็นโปรตีนของนิวโทรฟิล การทดสอบเชิงปริมาณหลายชนิดใช้ค่าต่ำกว่า 7.25 µg/g เป็นค่าลบ แต่ค่าขีดจำกัดของห้องปฏิบัติการจะแตกต่างกันไป.
- เครื่องหมายอุจจาระสูง บ่งชี้การอักเสบของลำไส้ ไม่ใช่การวินิจฉัยที่เฉพาะเจาะจง การติดเชื้อ, NSAIDs, diverticulitis และ colorectal neoplasia สามารถทำให้ทั้งสองค่าสูงขึ้นได้.
- calprotectin ຂອບເຂດ ของ 50–150 µg/g มักจะสมควรได้รับการตรวจซ้ำหลังจาก 2–6 สัปดาห์ แทนที่จะเป็นการส่องกล้องตรวจลำไส้ใหญ่ทันที.
- แคลโปรเทคตินสูงกว่า 250 µg/g เพิ่มความกังวลเกี่ยวกับการอักเสบของเยื่อเมือกที่กำลังดำเนินอยู่ และโดยทั่วไปจะกระตุ้นให้มีการทบทวนทางคลินิก การทดสอบการติดเชื้อในอุจจาระ หรือการวางแผนการส่องกล้อง.
- ຜົນກວດປົກກະຕິ *sa* **t** *u* **m** *n* **a** *h* **m** *n* **a** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** **n** **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **o** **h** *n* **o** *n* **a** **h** *n* **o** *n* **a** *n* **.
- IBD monitoring uses symptoms plus biomarkers, CRP, anemia markers, imaging and endoscopy; neither stool marker independently diagnoses a flare.
- ອາການດ່ວນ such as black stool, persistent visible blood, fever, severe pain, fainting or dehydration need medical assessment regardless of a marker result.
คุณควรเลือกเครื่องหมายอุจจาระตัวใดก่อน?
Fecal calprotectin is usually the first-choice stool inflammation marker because it is widely available, quantitative, and has the strongest role in separating likely inflammatory bowel disease from functional bowel symptoms. ការធ្វើតេស្ត lactoferrin ក្នុងលាមក results are a sensible alternative when that is the locally validated assay, but ordering both at the outset rarely changes care.
For a person with 6 weeks of loose stools, cramping, and no weight loss or rectal bleeding, I would generally begin with calprotectin plus targeted infection testing rather than colonoscopy. A result below 50 µg/g makes significant colonic inflammation less likely, while a clearly elevated result provides a reason to look further. The AGA guideline for chronic watery diarrhoea supports calprotectin or lactoferrin as screening tests for inflammatory conditions (Smalley et al., 2019).
Choose lactoferrin when your gastroenterology service uses it consistently, when the laboratory reports a validated quantitative value, or when it is bundled with an infectious diarrhoea work-up. Do not choose it because it sounds more specific: both proteins are released when neutrophils enter the bowel lumen. The practical issue is whether your clinician can compare the result with your prior samples using the same assay.
ແຄນເທສຕີ ເປັນ AI ເຄື່ອງວິເຄາະເລືອດ that places related results such as hemoglobin, CRP, albumin and iron indices alongside a stool-marker report; it does not replace the stool assay or a clinician’s diagnosis. If fatigue accompanies diarrhoea, a blood test for diarrhoea can help identify dehydration, anemia, or electrolyte loss that changes urgency.
A useful rule of thumb
Use one validated marker first, repeat the same marker when a result is borderline or when monitoring treatment, and reserve dual testing for a specific gastroenterology question. Changing assay halfway through follow-up creates apparent trends that may be laboratory noise rather than biology.
สิ่งที่แคลโปรเทคตินในอุจจาระตรวจจับได้จริง
Calprotectin measures a calcium- and zinc-binding protein released predominantly from neutrophils in the intestinal tract. A higher stool concentration reflects neutrophil migration into the gut, which is common in active IBD but also occurs with several non-IBD conditions.
Calprotectin is the S100A8/S100A9 protein complex, and it remains relatively stable in stool for several days at room temperature—one reason it works well as a home collection test. Its biological strength is locality: unlike CRP, it reflects cellular activity in the intestinal lumen rather than a whole-body acute-phase response. A normal CRP therefore does not cancel a high calprotectin result.
In adult practice, laboratories commonly classify less than 50 µg/g as normal and more than 150–250 µg/g as increasingly compatible with active intestinal inflammation. These are decision thresholds, not universal biological borders. Some European services use 100 µg/g as the referral threshold, while pediatric and assay-specific reference intervals can differ substantially.
I have seen a 28-year-old with a calprotectin of 680 µg/g, a normal CRP, and ultimately ulcerative colitis limited to the rectum and sigmoid colon. That pattern is not unusual: local mucosal inflammation can be active without a strong systemic signal. Our fecal calprotectin range guide explains why the laboratory’s own method and units should stay attached to every result.
สิ่งที่แลคโตเฟอร์รินในอุจจาระตรวจจับได้แตกต่างกัน
Lactoferrin detects another neutrophil-derived protein and answers nearly the same biological question as calprotectin: is there active intestinal neutrophil inflammation? It does not identify ulcerative colitis, Crohn’s disease, bacterial colitis, or another cause on its own.
Lactoferrin is an iron-binding glycoprotein stored in neutrophil secondary granules and released during activation. A positive qualitative fecal lactoferrin test is useful because it argues against uncomplicated IBS in the right clinical setting. Quantitative assays vary: one commonly used method defines a negative value as less than 7.25 µg/g, so never apply a calprotectin cutoff to a lactoferrin report.
The evidence does not show that lactoferrin is categorically superior. In a diagnostic meta-analysis, Wang and colleagues found fecal lactoferrin had pooled sensitivity of 82% and specificity of 95% for distinguishing IBD from non-IBD controls, although accuracy estimates shift with disease prevalence and study design (Wang et al., 2015). That impressive specificity still does not convert a positive result into an IBD diagnosis.
A positive lactoferrin result is especially worth discussing when diarrhoea began abruptly after travel, antibiotics, contaminated food exposure, or contact with someone unwell. In those situations, clinicians usually add pathogen testing rather than jumping straight to an IBD label. Our guide to លទ្ធផលដាំវប្បធម៌លាមក covers what a negative or mixed-growth report can and cannot settle.
วิธีอ่านค่าขีดจำกัดโดยไม่ตื่นตระหนกเกินไป
A calprotectin value below 50 µg/g is usually normal for adults, 50–150 µg/g is often an indeterminate zone, and values above 250 µg/g raise concern for active inflammation. Lactoferrin uses assay-specific cutoffs, commonly a qualitative positive or a quantitative threshold near 7.25 µg/g.
The 50 µg/g calprotectin threshold is designed for sensitivity: it catches most clinically significant inflammatory disease at the cost of some false positives. The 250 µg/g threshold is more useful for specificity and for monitoring established IBD. Between them lies the frustrating middle, where medication exposure, recent gastroenteritis, age, and trajectory matter more than a single number.
A change from 72 to 94 µg/g is often less meaningful than a change from 85 to 430 µg/g, particularly if both samples were tested by the same laboratory. Stool consistency can influence extraction and biological variation is real. Dr. Thomas Klein’s practical advice is to record NSAID use, recent infection, menstrual contamination, and collection date before interpreting a modest rise.
For a disciplined approach to serial values, compare the sample date with symptoms and related labs rather than treating every flagged result as disease progression. Our 3-10 mEq/L ໂດຍບໍ່ນັບ potassium; 8-16 mEq/L ໂດຍນັບ potassium explains the same principle of reference change and analytic variation in laboratory medicine.
เหตุใดเครื่องหมายทั้งสองจึงสามารถสูงได้โดยไม่มี IBD
Elevated stool inflammation markers occur with enteric infection, NSAID exposure, diverticulitis, colorectal neoplasia, microscopic colitis and IBD. The result confirms an inflammatory signal; it does not disclose the cause, location, duration, or severity by itself.
Non-steroidal anti-inflammatory drugs can raise fecal calprotectin, sometimes substantially, by increasing intestinal permeability and causing small mucosal injuries. Ibuprofen, naproxen and diclofenac matter; a clinician may suggest withholding them if medically safe before repeating the test. Do not stop prescribed aspirin, anticoagulants, or pain medicines without asking the prescriber first.
Acute bacterial gastroenteritis may produce calprotectin values above 500 µg/g and a positive lactoferrin, which is why a stool pathogen panel can be more informative than an urgent colonoscopy in the first days of illness. Conversely, giardiasis may cause prolonged diarrhoea with less striking neutrophilic marker elevation. The symptom timeline often carries more diagnostic weight than patients expect.
ແຄນເທສຕີ ເປັນ ບໍລິການຕີຄວາມຜົນການກວດຂອງ AI that can flag an inflammation pattern such as low hemoglobin, low albumin, thrombocytosis and raised CRP for clinician review, but those blood findings do not prove the source is intestinal. For people with blood in the stool, FIT follow-up and colonoscopy timing is a separate issue from calprotectin and should not be delayed.
เมื่อผลลัพธ์ปกติยังคงพลาดการวินิจฉัยโรคได้
Normal calprotectin or lactoferrin makes active colonic inflammation less likely, but it cannot fully exclude Crohn’s disease, particularly mild or isolated small-bowel disease. A normal result also does not explain persistent weight loss, iron-deficiency anemia, nocturnal diarrhoea, or recurrent visible bleeding.
Small-bowel Crohn’s disease can shed less neutrophil protein into a stool sample than extensive colitis, especially when lesions are proximal or mild. This is one reason symptoms and alarm features overrule a reassuring number. The ECCO-ESGAR diagnostic guideline recommends integrating biomarkers with ileocolonoscopy and cross-sectional imaging when IBD remains clinically suspected (Maaser et al., 2019).
A 46-year-old with calprotectin of 38 µg/g, ferritin of 7 ng/mL, and progressive fatigue deserves evaluation for gastrointestinal blood loss or malabsorption even if bowel frequency is normal. In my experience, the combination of iron deficiency and unexplained symptoms is much more consequential than a single low stool marker. Read our low ferritin and gut clues for the usual next laboratory questions.
Celiac disease, bile acid diarrhoea, pancreatic insufficiency and many medication effects may cause symptoms with normal stool inflammation markers. A normal test is therefore a fork in the road toward non-inflammatory diagnoses, not a declaration that symptoms are psychological or unimportant.
จะทำอย่างไรกับผลแคลโปรเทคตินที่ก้ำกึ่ง
A borderline fecal calprotectin result of 50–150 µg/g is commonly repeated after 2–6 weeks if symptoms are stable and there are no alarm features. The repeat should use the same laboratory method and should be timed away from a recent gastrointestinal infection where possible.
Before retesting, clinicians review NSAIDs, proton-pump inhibitors, antibiotics, acute infections, strenuous endurance exercise and age-related risk. There is no universally agreed washout interval for every medicine. A pragmatic plan is often 2 weeks after an acute illness has settled, provided symptoms do not signal a need for earlier care.
If the repeat falls from 118 to 32 µg/g and symptoms settle, invasive testing may be avoidable. If it rises from 96 to 310 µg/g, the direction adds useful evidence even before an endoscopy result arrives. This is why a single borderline value should rarely trigger panic—or false reassurance.
ຂອງພວກເຮົາ borderline calprotectin follow-up guide lays out the questions to bring to a primary-care or gastroenterology appointment. A short symptom diary with stool frequency, nighttime waking, fever and medication dates is usually more useful than obsessively checking food triggers.
แพทย์ใช้วิธีประเมินเครื่องหมายหลังจากวินิจฉัย IBD แล้วอย่างไร
In established IBD, calprotectin is most useful for tracking objective intestinal inflammation and helping decide whether symptoms represent a flare, infection, IBS overlap, or treatment failure. Lactoferrin can also follow activity, but calprotectin has more guideline-supported thresholds for treat-to-target monitoring.
Symptoms and mucosal activity frequently diverge. A patient with ulcerative colitis may feel well while calprotectin climbs from 80 to 360 µg/g, or have urgent bowel motions from bile acid malabsorption while calprotectin remains 28 µg/g. The 2023 AGA ulcerative colitis biomarker guideline advises combining symptoms with biomarkers rather than relying on either alone (Singh et al., 2023).
For remission monitoring, many clinicians view less than 150 µg/g as reassuring, while more than 150 µg/g may warrant repeat testing, endoscopy, or treatment review depending on symptoms and prior disease behaviour. In active symptomatic ulcerative colitis, more than 250 µg/g supports ongoing inflammation. Cutoffs are guides, not instructions to alter biologic treatment without specialist input.
Kantesti AI គឺជាអ្វីមួយដែល ແພລດຟອມການຕີຄວາມໝາຍ biomarker ຂອງ AI that organizes blood-test trends around a patient’s reported treatment dates; it cannot assess stool endoscopic severity from a number alone. Patients taking biologics should also understand which blood safety tests monitor treatment and which symptoms require prompt contact with their IBD team.
ความผิดพลาดในการเก็บตัวอย่างและเวลาส่งผลต่อผลลัพธ์อย่างไร
Collection quality affects stool marker interpretation because a contaminated, delayed, or poorly sampled specimen can be rejected or produce a less reliable measurement. Most laboratories want a small stool portion placed into the supplied sterile container without toilet water or urine.
Loose stool is usually acceptable for calprotectin and lactoferrin testing; do not wait for a formed sample if diarrhoea is the clinical problem. Avoid collecting from toilet water, and tell the laboratory if the sample includes visible menstrual blood. Storage instructions vary by kit, but many allow short room-temperature transport because calprotectin is comparatively stable.
Sampling a day after a marathon, a bout of gastroenteritis, or colonoscopy bowel preparation may answer the wrong question. Endurance exercise can transiently increase gut permeability and provoke gastrointestinal symptoms. If you are an endurance athlete without red flags, consider timing collection away from a major event; our คู่มือแล็บสำหรับนักกีฬาที่เน้นความอึด explains why context changes test interpretation.
The thing is, a perfect collection does not make a nonspecific biomarker specific. A high-quality sample improves confidence in the measurement; it cannot replace the clinical history, examination, and differential diagnosis.
การตรวจเลือดใดที่ทำให้เครื่องหมายอุจจาระมีประโยชน์มากขึ้น
A CBC, CRP, ferritin, albumin, kidney function and celiac serology often add more clinical value to a raised stool marker than ordering a second stool inflammation protein. The concerning pattern is not any one abnormality but several results that point toward inflammation, malabsorption, or blood loss.
Low hemoglobin, ferritin below 15 ng/mL, albumin below the laboratory reference range, raised platelets, or raised CRP can strengthen concern for clinically meaningful bowel disease. None is diagnostic of IBD. In fact, CRP may remain normal in mild ulcerative colitis, and ferritin can look falsely normal when inflammation raises it as an acute-phase protein.
ແຄນເທສຕີ ເປັນ ឧបករណ៍វិភាគតេស្តឈាមដែលដំណើរការដោយ AI that reads a CBC, iron studies and CRP in the same clinical frame, including whether a changing hemoglobin level might justify earlier review. Dr. Thomas Klein routinely cautions that an isolated CRP of 12 mg/L is nonspecific, whereas CRP 12 mg/L plus falling albumin and a calprotectin of 740 µg/g is a much more actionable cluster.
For patients whose iron values seem contradictory, our iron studies research guide explains transferrin saturation and ferritin during inflammation. A CBC result guide can also help you identify whether anemia is microcytic, inflammatory, or mixed.
เมื่อใดที่การสั่งตรวจทั้งสองอย่างอาจสมเหตุสมผล
Ordering calprotectin and lactoferrin together is usually unnecessary, but it can be reasonable when a specialist is reconciling discordant symptoms, a prior assay cannot be repeated, or a local pathway requires confirmation. Concordant results modestly increase confidence in an inflammatory signal; discordant results usually trigger review, not arithmetic averaging.
A high calprotectin with negative lactoferrin may reflect assay timing, a result near the cutoff, specimen heterogeneity, or analytical differences. A low calprotectin with positive lactoferrin deserves the same disciplined response: verify collection, review the exact assay, check symptoms and test for infection when appropriate. Neither combination has a validated shortcut to diagnosis.
Dual testing can also be useful in research settings where a protocol prespecifies both biomarkers. That is different from routine patient care, where duplicate testing can add cost without improving decisions. Ask the ordering clinician a simple question: “What will we do differently if the second test is positive?”
If a report looks internally inconsistent, use our แนวทางการทดสอบเชิงคุณภาพเทียบกับเชิงปริมาณ to understand why “positive” and “high” are not interchangeable laboratory statements. Consistency of method matters more than collecting every available marker.
สิ่งใดที่ยืนยันหรือตัด IBD ออกไปได้จริง
IBD is diagnosed through a synthesis of symptoms, ileocolonoscopy with tissue sampling, histology, laboratory tests, and sometimes MRI or CT enterography—not from calprotectin or lactoferrin alone. Stool markers help decide who needs these investigations and whether inflammation may be changing over time.
Colonoscopy allows direct assessment of the terminal ileum and colon and permits tissue examination for chronic inflammatory features, infection, microscopic colitis, dysplasia, and other causes. Imaging is particularly valuable when Crohn’s disease may involve small bowel beyond the reach of a standard colonoscopy. A stool marker is a triage signal, not a microscopic diagnosis.
Do not confuse a fecal immunochemical test with either inflammatory marker. FIT detects human hemoglobin and is used primarily in colorectal cancer screening or lower-GI bleeding pathways, whereas calprotectin and lactoferrin detect neutrophil products. Our comparison of FIT and FOBT explains why a negative inflammation marker does not substitute for recommended cancer screening.
As of September 4, 2026, no major gastroenterology guideline recommends diagnosing Crohn’s disease or ulcerative colitis from a single stool biomarker threshold. That restraint protects patients from both missed disease and unnecessary lifelong diagnostic labels.
อาการที่สำคัญกว่าผลการตรวจอุจจาระใดๆ
Persistent visible rectal bleeding, black tarry stool, severe abdominal pain, fever, fainting, dehydration, rapidly worsening weakness, or unintended weight loss need timely medical assessment regardless of calprotectin or lactoferrin. A normal result should never be used to wait out a potentially urgent symptom pattern.
The urgent concern is physiology, not the label on a laboratory report. Frequent watery diarrhoea can produce low potassium, acute kidney injury, and orthostatic symptoms before an inflammation marker returns. Adults with inability to keep fluids down, confusion, fainting, or minimal urine output should seek urgent care.
New bowel symptoms after age 50, a strong family history of colorectal cancer, and iron-deficiency anemia alter the threshold for colon evaluation even when calprotectin is low. A stool marker does not assess cancer risk comprehensively. Our mucus in stool red-flag guide distinguishes common benign patterns from symptoms that need examination.
Children, pregnant people, older adults, and people using immune-suppressing medicines need individualized triage because their baseline risks differ. If you are unsure whether symptoms are urgent, contacting a local clinician or urgent-care service is safer than trying to interpret a number in isolation.
การสนทนาที่นำไปปฏิบัติได้จริงหลังจากทราบผลของคุณ
The most useful follow-up question is: “Does this result change my need for infection testing, repeat testing, imaging, or endoscopy?” Bringing the exact value, assay name, symptom timeline, medicines, and previous results makes that conversation faster and more clinically precise.
Bring a list of the previous 14 days: stool frequency, overnight symptoms, fever, weight change, travel, antibiotics, NSAIDs, and family history. A calprotectin of 180 µg/g after a 3-day febrile diarrhoeal illness calls for a different plan than the same result after 4 months of nocturnal diarrhoea and weight loss.
Kantesti AI can help you organize accompanying blood reports before an appointment, but diagnosis and treatment decisions belong with the clinician who can examine you and arrange definitive testing. Our ວິທີການຢືນຢັນທາງການແພດຂອງພວກເຮົາ explains how clinical oversight and source checking are built into responsible laboratory interpretation.
For complex cases, ask who will own the follow-up and when you should expect a repeat result or referral decision. The clinicians on our ຄະນະທີ່ປຶກສາທາງການແພດ emphasize that a documented plan beats a vague instruction to “recheck later,” especially when inflammation markers and anemia move in the same direction.
ข้อสรุปที่เน้นการตัดสินใจ
Choose calprotectin first in most settings, use lactoferrin when it is your service’s validated alternative, and do not assume either result diagnoses IBD. A low result shifts attention toward functional and non-inflammatory causes, while a persistently high result identifies people who may need infection testing, specialist review, or endoscopy.
For uncomplicated chronic diarrhoea, one normal marker—calprotectin below 50 µg/g or a negative lactoferrin according to that laboratory—can reduce the likelihood of active inflammatory disease. For a value above 250 µg/g or a positive lactoferrin with persistent symptoms, the next question is cause, not certainty. Infection, medicine exposure, IBD, and other inflammatory conditions remain on the list.
Most patients find the ambiguity hardest in the 50–150 µg/g calprotectin zone. In my experience, the best next step is usually a carefully timed repeat, not a dietary cleanse, self-directed steroid use, or an internet diagnosis. Keep the same laboratory where feasible so the trend is interpretable.
Kantesti’s ຄູ່ມືເທັກໂນໂລຍີ AI describes how our systems preserve laboratory context while highlighting questions for medical review. The safe use of any AI interpretation is the same here: use it to prepare for a better clinical conversation, never to override red flags or replace diagnostic care.
ຄໍາຖາມທີ່ຖາມເລື້ອຍໆ
Calprotectin ດີกว่า lactoferrin ในการตรวจหา IBD หรือไม่?
Calprotectin ມັກຖືກເລືອກໃຊ້ໃນກໍລະນີສົງໄສ IBD ເພາະວ່າມັນມີຢູ່ໃນການທົດສອບແບບປະລິມານທີ່ກວ້າງຂວາງ ແລະມີລະດັບການຕິດຕາມທີ່ໃຊ້ກັນທົ່ວໄປເຊັ່ນ: ໜ້ອຍກວ່າ 50 µg/g ແລະຫຼາຍກວ່າ 250 µg/g. Lactoferrin ກໍ່ເປັນຕົວຊີ້ບອກທີ່ເປັນປະໂຫຍດທີ່ມາຈາກເມັດເລືອດຂາວໃນອາຈົມ ແລະສາມາດປະຕິບັດໄດ້ດີເມື່ອຫ້ອງທົດລອງໃຊ້ວິທີວິເຄາະທີ່ໄດ້ຮັບການຮັບຮອງ. ບໍ່ມີຕົວຊີ້ບອກໃດຢືນຢັນ IBD, ເພາະວ່າການຕິດເຊື້ອ, NSAIDs, diverticulitis ແລະສະພາບລຳໄສ້ອື່ນໆ ສາມາດເພີ່ມທັງສອງຢ່າງໄດ້. ການທົດສອບທີ່ດີກວ່າ ປົກກະຕິແມ່ນການທົດສອບທີ່ທ່ານໝໍຂອງທ່ານ ສາມາດຕີຄວາມໝາຍໄດ້ຄຽງຄູ່ກັບອາການ ແລະເຮັດຊ້ຳໂດຍໃຊ້ວິທີການຫ້ອງທົດລອງດຽວກັນ.
ລະດັບ calprotectin ທີ່ໜ້າກັງວົນແມ່ນເທົ່າໃດ?
ລະດັບ calprotectin ໃນອາຈົມຕ່ຳກວ່າ 50 µg/g ໂດຍທົ່ວໄປແມ່ນເປັນທີ່ໜ້າພໍໃຈສຳລັບຜູ້ໃຫຍ່ທີ່ບໍ່ມີອາການເຕືອນ, ໃນຂະນະທີ່ 50–150 µg/g ມັກຈະຖືວ່າເປັນຂອບເຂດ ແລະ ອາດຈະເຮັດຊ້ຳໄດ້ຫຼັງຈາກ 2–6 ອາທິດ. ຄ່າທີ່ສູງກວ່າ 150–250 µg/g ຈະເຮັດໃຫ້ເປັນຫ່ວງຫຼາຍຂຶ້ນກ່ຽວກັບການອັກເສບຂອງລຳໄສ້, ແລະລະດັບທີ່ສູງກວ່າ 250 µg/g ມັກຈະຮຽກຮ້ອງໃຫ້ມີການທົບທວນທາງຄລີນິກ ຫຼື ການກວດເພີ່ມເຕີມ. ການປະຕິບັດທີ່ແນ່ນອນແມ່ນຂຶ້ນກັບການວິເຄາະ, ອາການ, ອາຍຸ, ການໃຊ້ NSAID ແລະວ່າຄ່ານັ້ນເພີ່ມຂຶ້ນຫຼືບໍ່. ຄ່າ 600 µg/g ຫຼັງຈາກອາການຖອກທ້ອງຈາກເຊື້ອແບັກທີເຣຍສ້ ັນແຫຼມອາດມີຄວາມໝາຍແຕກຕ່າງຈາກ 600 µg/g ໃນລະຫວ່າງອາການເຮື້ອຮັງຫຼາຍເດືອນ.
IBS ສາມາດເຮັດໃຫ້ມີຄາໂປແຄລໄຊນິນ ຫຼື ແລັກໂຕເຟີຣິນສູງໄດ້ບໍ?
IBS ที่ไม่ซับซ้อนมักจะไม่ก่อให้เกิด fecal calprotectin หรือ lactoferrin ที่สูงขึ้น เนื่องจาก IBS ไม่ได้ก่อให้เกิดการอักเสบของลำไส้ที่เกิดจากเม็ดเลือดขาว การสูงขึ้นเล็กน้อยของ calprotectin ระหว่าง 50 ถึง 150 µg/g อาจเกิดขึ้นจากการติดเชื้อเมื่อเร็วๆ นี้ การใช้ NSAIDs ปัจจัยที่เกี่ยวข้องกับอายุ หรือความแปรปรวนของการทดสอบ ดังนั้นจึงไม่สามารถตัด IBS ออกได้โดยอัตโนมัติ การตรวจพบ lactoferrin หรือ calprotectin เป็นบวกที่สูงกว่า 250 µg/g ควรได้รับการประเมินหาสาเหตุของการอักเสบหรือการติดเชื้อ แทนที่จะสันนิษฐานว่าเป็น IBS IBS และ IBD สามารถเกิดขึ้นร่วมกันได้ ซึ่งเป็นอีกเหตุผลหนึ่งที่อาการและแนวโน้มมีความสำคัญ.
Can a normal calprotectin rule out Crohn's disease?
ຜົນການກວດຄາໂປເທັກຕິນປົກກະຕິຈະຫຼຸດຜ່ອນຄວາມເປັນໄປໄດ້ຂອງພະຍາດລຳໄສ້ອັກເສບໃນລຳໄສ້ໃຫຍ່ (IBD) ທີ່ກຳລັງເປັນຢູ່, ແຕ່ບໍ່ສາມາດຍົກເວັ້ນພະຍາດໂຄຣົນ (Crohn’s disease) ໄດ້ຢ່າງສົມບູນ, ໂດຍສະເພາະແມ່ນພະຍາດໂຄຣົນທີ່ມີອາການບໍ່ຮຸນແຮງຫຼືເກີດຂຶ້ນຢູ່ໃນລຳໄສ້ນ້ອຍເທົ່ານັ້ນ. ຄ່າທີ່ຕ່ຳກວ່າ 50 µg/g ບໍ່ຄວນມີອິດທິພົນຕໍ່ອາການເຕືອນຕ່າງໆເຊັ່ນ: ໂລກເລືອດຈາງຂາດທາດເຫຼັກ, ນ້ຳໜັກລົດ, ທ້ອງເສຍໃນຕອນກາງຄືນ, ມີເລືອດອອກບໍ່ຢຸດຫຼືມີປະຫວັດຄອບຄົວທີ່ແຂງແຮງ. ແພດອາດໃຊ້ວິທີກວດດ້ວຍການສ່ອງກ້ອງລຳໄສ້ໃຫຍ່ (ileocolonoscopy), ການຖ່າຍຮູບສະແກນດ້ວຍຄື້ນແມ່ເຫຼັກ (MR enterography) ຫລືການກວດດ້ວຍແຄັບຊູນ (capsule assessment) ເມື່ອຄວາມສົງໄສທາງການແພດຍັງຄົງຢູ່ໃນລະດັບສູງ. ຜົນລັບດັ່ງກ່າວຄວນໄດ້ຮັບການພິຈາລະນາວ່າເປັນພຽງຂໍ້ມູນໜຶ່ງທີ່ປັບຄວາມເປັນໄປໄດ້ເທົ່ານັ້ນ, ບໍ່ແມ່ນການກວດເພື່ອຍົກເວັ້ນຂັ້ນສຸດທ້າຍ.
ຂ້ອຍຄວນເຮັດຊ້ຳຜົນ calprotectin ທີ່ບໍ່ແນ່ນອນບໍ?
ผล calprotectin ที่อยู่ในเกณฑ์ก้ำกึ่งที่ 50–150 µg/g มักจะตรวจซ้ำหลัง 2–6 สัปดาห์ เมื่ออาการคงที่และไม่มีสัญญาณอันตราย ก่อนทำการตรวจซ้ำ แพทย์มักจะทบทวนประวัติโรคกระเพาะและลำไส้อักเสบเมื่อเร็วๆ นี้ การใช้ยา NSAIDs ยาปฏิชีวนะ และสภาวะในการเก็บสิ่งส่งตรวจ เนื่องจากแต่ละปัจจัยอาจมีผลต่อค่าที่ได้ ควรใช้ชุดตรวจเดียวกันในห้องปฏิบัติการหากเป็นไปได้ เนื่องจากผลจากวิธีที่แตกต่างกันอาจไม่สามารถเปรียบเทียบกันได้โดยตรง ผลที่เพิ่มขึ้นเข้าใกล้หรือสูงกว่า 250 µg/g โดยทั่วไปมีน้ำหนักทางคลินิกมากกว่าค่าที่สูงขึ้นเล็กน้อยอย่างคงที่.
ยาปฏิชีวนะสามารถส่งผลต่อ calprotectin และ lactoferrin ในอุจจาระได้หรือไม่?
ຢາຕ້ານເຊື້ອສາມາດສົ່ງຜົນກະທົບຕໍ່ເຄື່ອງໝາຍການອັກເສບຂອງອາຈົມໂດຍທາງອ້ອມ ໂດຍການປິ່ນປົວ, ກະຕຸ້ນ, ຫຼືເກີດຂຶ້ນພ້ອມກັບການຖອກທ້ອງຈາກການຕິດເຊື້ອ ແລະ ໂດຍການປ່ຽນແປງຈຸລິນຊີໃນລຳໄສ້. ບຸກຄົນທີ່ຖອກທ້ອງຈາກຢາຕ້ານເຊື້ອຄວນໄດ້ຮັບການປະເມີນຫາສາເຫດເຊັ່ນ Clostridioides difficile ແທນທີ່ຈະຕີຄວາມໝາຍ calprotectin ທີ່ສູງຂຶ້ນ ຫຼື lactoferrin ທີ່ເປັນບວກວ່າເປັນ IBD. ບໍ່ມີວັນເວລາທີ່ເຊື່ອຖືໄດ້ໃນການລໍຖ້າຫຼັງຈາກກິນຢາຕ້ານເຊື້ອ ກ່ອນທີ່ຈະກວດ; ເວລາຂຶ້ນກັບອາການ ແລະຄຳຖາມທາງຄລີນິກ. ການຖອກທ້ອງ, ໄຂ້, ຫຼືອາການເຈັບທ້ອງຢ່າງຕໍ່ເນື່ອງຫຼັງຈາກກິນຢາຕ້ານເຊື້ອຕ້ອງການການກວດຈາກແພດ ບໍ່ແມ່ນການປິ່ນປົວດ້ວຍຕົນເອງ.
ຮັບການວິເຄາະຜົນກວດເລືອດດ້ວຍ AI ທັນທີ
ເຂົ້າຮ່ວມຜູ້ໃຊ້ຫຼາຍກວ່າ 2 ລ້ານຄົນທົ່ວໂລກ ທີ່ໄວ້ໃຈ Kantesti ສຳລັບການວິເຄາະການກວດເລືອດທີ່ທັນທີ ແລະຖືກຕ້ອງ. ອັບໂຫຼດຜົນກວດເລືອດຂອງທ່ານ ແລະຮັບການຕີຄວາມໝາຍຢ່າງຄົບຖ້ວນຂອງ biomarker 15,000+ ໃນວິນາທີ.
📚 ບົດຄວາມວິຈັຍທີ່ອ້າງອີງ
Klein, T., Mitchell, S., & Weber, H. (2026). Kantesti LTD. (2026). Urobilinogen in Urine Test: Complete Urinalysis Guide 2026. Zenodo.. ການຄົ້ນຄວ້າທາງການແພດຂອງ AI Kantesti.
Klein, T., Mitchell, S., & Weber, H. (2026). Kantesti LTD. (2026). Iron Studies Guide: TIBC, Iron Saturation & Binding Capacity. Zenodo.. ການຄົ້ນຄວ້າທາງການແພດຂອງ AI Kantesti.
📖 ເອກະສານອ້າງອີງທາງການແພດພາຍນອກ
Singh S et al. (2023). AGA Clinical Practice Guideline on the Role of Biomarkers for the Management of Ulcerative Colitis. Gastroenterology.
📖 ສືບຕໍ່ອ່ານ
ສຳຫຼວດຄູ່ມືທາງການແພດທີ່ຜ່ານການກວດສອບຈາກຜູ້ຊ່ຽວຊານຈາກ Kantesti ທີມການແພດ:

ผล FIT เป็นบวก: ความเร่งด่วน การส่องกล้องลำไส้ใหญ่ และขั้นตอนต่อไป
ການຕີຄວາມໝາຍຜົນການກວດຮ່າງກາຍ 2026 ອັບເດດ ທີ່ເຂົ້າໃຈງ່າຍ ຜົນການກວດ FIT ທີ່ເປັນບວກໝາຍຄວາມວ່າພົບທາດເຫຼັກຂອງມະນຸດໃນ...
ອ່ານບົດຄວາມ →
ສາເຫດຂອງປັດສະວະເປັນຟອງ: ເມື່ອໃດທີ່ຟອງທີ່ເກີດຂຶ້ນຊ້ຳໆ ຕ້ອງການການກວດສອບ
ການຕີຄວາມໝາຍຜົນກວດຫ້ອງທົດລອງກ່ຽວກັບສຸຂະພາບໝາກໄຂ່ຫຼັງ 2026 ສະບັບປັບປຸງ ເປັນມິດກັບຄົນເຈັບ ຟອງນ້ອຍໆສອງສາມຟອງຫຼັງຈາກນໍ້າປັດສາວະອອກໄວໆ ໂດຍທົ່ວໄປແລ້ວແມ່ນກົນໄກທາງຟີຊິກ...
ອ່ານບົດຄວາມ →
Hematuria ຂອງນັກກິລາກາງແຂນ: ຍ່ຽວສີບົວຫຼັງຈາກອອກກຳລັງກາຍ ໄດ້ອະທິບາຍແລ້ວ
ພະຍາດກິລາ ການວິເຄາະນໍ້າຕານ 2026 ຂໍ້ມູນອັບເດດ ເປັນມິດກັບຄົນເຈັບ ນໍ້າຕານສີບົວ ຫຼືສີນ້ຳຕານຫຼັງຈາກແລ່ນເປັນເວລາດົນ ມັກຈະ...
ອ່ານບົດຄວາມ →
ການກວດເລືອດຫາໂລຫະໜັກ: ໄລເວລາ, ການນຳໃຊ້ ແລະ ຂໍ້ຈຳກັດ
ການຕີຄວາມໝາຍຫ້ອງທົດລອງສຸຂະພາບສິ່ງແວດລ້ອມ 2026 ການອັບເດດ ທີ່ເປັນມິດກັບຄົນເຈັບ ການກວດເລືອດຫາໂລຫະໜັກແມ່ນດີທີ່ສຸດສຳລັບການ...
ອ່ານບົດຄວາມ →
ໂຮໂມທາມາດາລິນ ຫລັງຈາກ B12: ເມື່ອຜົນການທົດສອບຕົວຈິງເຮັດໃຫ້ເຂົ້າໃຈຜິດ
2026 ການຕີຄວາມໝາຍຫ້ອງທົດລອງ Vitamin B12 ການອັບເດດທີ່ເຂົ້າໃຈງ່າຍສຳລັບຄົນເຈັບ ຜົນ Vitamin B12 ທີ່ເປັນປົກກະຕິຫຼັງຈາກການເສີມອາດຈະບັນທຶກເມື່ອບໍ່ດົນມານີ້...
ອ່ານບົດຄວາມ →
ການກວດເລືອດສຳລັບແມ່ຍິງອາຍຸ 60 ປີຂຶ້ນໄປ: ລຳດັບຄວາມສຳຄັນຕາມຄວາມສ່ຽງ
ຫ້ອງທົດລອງສຸຂະພາບແມ່ຍິງ ການຕີຄວາມໝາຍ 2026 ການອັບເດດ ເປັນມິດກັບຄົນເຈັບ ແຜນການກວດຫ້ອງທົດລອງທີ່ເປັນປະໂຫຍດຫຼັງຈາກອາຍຸ 60 ປີແມ່ນຂັບເຄື່ອນໂດຍຄວາມສ່ຽງ, ຢາ,...
ອ່ານບົດຄວາມ →ຄົ້ນພົບຄູ່ມືດ້ານສຸຂະພາບທັງໝົດຂອງພວກເຮົາ ແລະ ເຄື່ອງມືການວິເຄາະຜົນກວດເລືອດດ້ວຍ AI ທີ່ kantesti.net
⚕️ ຂໍ້ສັງເກດທາງການແພດ
ບົດຄວາມນີ້ມີຈຸດປະສົງເພື່ອການສຶກສາເທົ່ານັ້ນ ແລະບໍ່ແມ່ນຄຳແນະນຳທາງການແພດ. ຄວນປຶກສາຜູ້ໃຫ້ບໍລິການດ້ານສຸຂະພາບທີ່ມີຄຸນວຸດທິສະເໝີ ສຳລັບການວິນິດໄຊ ແລະ ການຕັດສິນໃຈດ້ານການຮັກສາ.
ສັນຍານຄວາມໄວ້ໃຈ E-E-A-T
ປະສົບການ
ການທົບທວນຄລີນິກຂອງແພດຜູ້ນຳພາ ກ່ຽວກັບຂັ້ນຕອນການຕີຄວາມໝາຍຜົນການກວດໃນຫ້ອງທົດລອງ.
ຄວາມຊ່ຽວຊານ
ວິຊາການແພດທົດລອງ (ການແພດທາງຫ້ອງທົດລອງ) ເນັ້ນໃສ່ວ່າຕົວຊີ້ວັດ (biomarkers) ມີພຶດຕິກຳແນວໃດໃນບັນບົດທາງຄລີນິກ.
ຄວາມເປັນອຳນາດ
ຂຽນໂດຍທ່ານດຣ. Thomas Klein ໂດຍມີການກວດທານໂດຍທ່ານດຣ. Sarah Mitchell ແລະ ສາດສະດາຈານດຣ. Hans Weber.
ຄວາມໜ້າເຊື່ອຖື
ການຕີຄວາມໝາຍອີງຕາມຫຼັກຖານດ້ວຍເສັ້ນທາງຕິດຕາມທີ່ຊັດເຈນ ເພື່ອຫຼຸດການຕົກໃຈ.